TNFSF10 and Alzheimer disease: Considering that nanomedicine and IN route represent interesting approaches for brain targeting [21], we aimed to develop and compare lipidic and polymeric nanomedicines, for more effective delivery of a TRAIL-neutralizing monoclonal antibody to the brain via the N2B route and successful treatment of neurodegenerative disorders, such as AD.